Compare CIGI & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIGI | GRFS |
|---|---|---|
| Founded | 1972 | 1940 |
| Country | Canada | Spain |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.2B |
| IPO Year | N/A | 2006 |
| Metric | CIGI | GRFS |
|---|---|---|
| Price | $110.23 | $9.54 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $175.00 | $10.15 |
| AVG Volume (30 Days) | ★ 541.1K | 438.5K |
| Earning Date | 02-13-2026 | 07-28-2022 |
| Dividend Yield | 0.27% | ★ 1.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.02 | 0.64 |
| Revenue | $5,558,462,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $17.67 | $5.36 |
| Revenue Next Year | $7.35 | $5.15 |
| P/E Ratio | $55.94 | ★ $18.24 |
| Revenue Growth | ★ 15.27 | 7.31 |
| 52 Week Low | $98.97 | $6.19 |
| 52 Week High | $171.51 | $11.14 |
| Indicator | CIGI | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 26.50 | 57.30 |
| Support Level | $98.97 | $9.07 |
| Resistance Level | $147.61 | $9.64 |
| Average True Range (ATR) | 7.74 | 0.22 |
| MACD | -2.63 | 0.01 |
| Stochastic Oscillator | 23.93 | 82.30 |
Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are; Real Estate Services, Engineering, Investment Management, and Corporate. Maximum revenue for the company is generated from its Real Estate Services segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, property sales brokerage, and lease brokerage services, among others. Geographically, the company generates maximum revenue from the United States and the rest from Canada, Australia, the United Kingdom, Poland, China, India, and other regions.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.